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Introduction
T
he  World  Health  Organization  (WHO) 
has  reported  chronic  liver  disease  to  be 
responsible for 1.4 million deaths worldwide in 2002. 
Hepatitis C virus (HCV) stands as one of the most 
important etiologies of chronic liver disease and is 
an emerging infection in the world and in Iran (1). It 
seems that less than 1% of Iranians are infected with 
HCV infection (2). The control of HCV is possible 
and it needs to be eradicated with the best approved 
drugs (3). Hepatitis B virus (HBV) infection is also 
an important health problem worldwide and about 
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Background and Aims: The main purpose of treating and caring for patients with chronic viral hepatitis is to promote life 
satisfaction and a feeling of well-being in patients suffering from this disease. The aim of this study was to evaluate the 
effect of education on quality of life in patients with chronic hepatitis who were treated with Interferon alpha.
Methods: This quasi-experimental study was conducted on 60 patients with viral hepatitis. The intervention included 
teaching them the method of self injection of Interferon alpha 2 b, giving them educational pamphlets and then following 
their continuing treatment with interferon. Patients were randomly assigned to two 30-patient groups. The data- gather-
ing tool was a demographic characteristics questionnaire and the Quality of Life Questionnaire for Patients with Chronic 
Liver Disease (CLDQ). The educational program was done in four 45- minute sessions for the case group and their rela-
tives. The follow-up period was 12 weeks. Quality of life in patients with chronic hepatitis was measured before initiating 
interferon therapy, and after the educational period. Quality of life in the two groups was compared.
Results:  The  total  quality  of  life  score  in  the  two  groups  before  therapy  did  not  show  any  significant  difference 
(P = 0.351); while 12 weeks after education there was a significant difference between the two groups (P < 0.001) in 
three items including abdominal symptoms (P = 0.01), worry (P < 0.001) and emotional factors (P < 0.001). The other 
three items did not show a significant difference between the two groups. The total quality of life score in the case group 
was significantly different before and after education (P < 0.001), and improved after education. The total quality of life 
score in the control group did not differ significantly after 12 weeks (P = 0.143).
Conclusions: Planning short and simple educational programs has a significant effect on the patient’s control of his/her 
disease and its side effects; and can improve quality of life, life satisfaction, and mechanisms of coping with treatment 
in patients with viral hepatitis.
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1,400,000-2,000,000 patients suffer from it in Iran 
(4). The  main  effective  drugs  in  the  treatment  of 
HCV infection is alpha interferon plus ribavirin and 
alpha interferon is also one of the approved therapies 
in  chronic  hepatitis  B  (5,  6).  Several  studies  have 
documented that impaired health-related quality of 
life (HRQoL) is associated with chronic hepatitis B 
and C (7, 8). Studies have shown that the progression 
of  liver  disease  and  ineffective  antiviral  therapies 
increasingly affect the quality of life, and the mental 
and physical well-being of patients (9). The side effects 
of  interferon  therapy,  including  an  influenza-like 
syndrome, affect the quality of life of patients as well 
(10). The quality of life effects of treatment regimens 
also  affect  adherence  to  treatment  regimens  (11). 
During therapy with alpha-2b interferon, patients 
should be closely monitored for side effects (10), so 
appropriate and timely supervision during treatment 
is  necessary  to  limit  these  effects  (11).  Frequently 
treatment causes fatigue, muscular pain, influenza-
like  symptoms,  changes  in  the  mental  status  and 
sexual desires of the patient, which will negatively 
affect the patient’s life, social communication and 
abilities  (12). The importance of these side effects 
forms the basis of the physician’s and the patient’s 
decision-making regarding the continuation of the 
therapy, or of the cessation of the course of therapy 
before its completion. Termination of therapy before 
its completion shows the patient’s intolerance (12). 
Side effects of Interferon alpha begin a few hours 
after  its  administration  and  the  patient  develops 
tolerance in a few weeks with continuation of therapy 
(13). Patient education and effective treatment are 
the cornerstones for enabling the patient to adhere 
to  a  therapeutic  regimen.  Monitoring  the  patient 
and dose adjustment during the treatment period is 
necessary (14). At times lack of awareness about the 
route of application results in early termination of the 
treatment (12); as a result, a study of the education of 
the patient in the proper method of the self- injection 
of interferon and the method of familiarizing him or 
her with the side effects and strategies of coping is 
essential and will lead to an improved quality of life. 
This study had been conducted for these reasons.
Our  primary  goal  was  to  study  the  effect  of 
education on the quality of life of the patient suffering 
from chronic hepatitis B and C under treatment with 
Interferon alpha.
Materials and Methods
This  is  a  quasi-experimental  study  in  a  pretest-
posttest method conducted at Tehran Hepatitis Center- 
Baqiyatallah  Research  Center  for  Gastroenterology 
and Liver Diseases. Sampling was nonrandomized and 
based on sample characteristics (age 18-60 yrs, absence 
of  other  infections  and  chronic  diseases,  first  time 
treatment for Interferon alpha therapy and absence of 
cirrhosis). Sixty patients were randomly assigned to the 
two 30-patient groups of cases and controls. Following 
referral to Tehran Hepatitis Center, patients fulfilling 
our selection criteria and willing to participate in the 
study were assigned to the case and control groups one 
after the other. The Quality of Life Questionnaire for 
Patients with Chronic Liver Disease (CLDQ) and the 
demographic information of the patients were filled 
out anonymously and codes were used with the help 
of the researcher.
The CLDQ is the first tool to assess quality of life 
in chronic liver disease patients reasonably adjusted 
to  include  fatigue,  activity,  emotional  symptoms, 
abdominal symptoms, systemic symptoms and worry. 
The scores are graded from 1 to 7 for each category 
making  the  minimum  possible  scores  29  and  the 
maximum 203. The validity and reproducibility of 
this questionnaire had been previously studied in Iran 
(15, 16). The eliability of the CLDQ was measured 
by internal consistency using Cronbach’s alpha test 
with a reported consistency of over 95%. 
Cases were asked to write down their free time 
on the back of the questionnaire to set up times 
for their education classes. These classes were held 
once a week and in each class educational pamphlets 
were distributed among the cases. Follow-up of the 
patients was done as self-reporting with in-person 
attendance every month. Each educational session 
had a maximum of 6 patients and 6 accompanying 
persons..  These  accompanying  persons  had  a 
supportive care role. The sequence of the classes was 
as follows: 
In the first session, the goals of our study, the nature 
of their disease, transmission routes, the diagnosis 
and treatment of their disease were explained and 
pamphlets were distributed to the patients. In the 
second session, the effect of interferon therapy on 
their disease, the frequent side effects after injection, 
methods  of  protecting  themselves  and  controlling 
these side effects were explained and pamphlets were 
distributed. In the third session, the method of the 
self-injection  of  interferon  was  explained  and  the 
patients’ questions were answered. A pamphlet was 
also given out. In the fourth session, the injection 
of interferon by the patient was observed and their 
problems, if any, were corrected. Educational sessions 
were held for a month and patients were followed 
for 12 weeks. At the time of entering the study and 
12 months after initiation of therapy, patients were 
asked to fill the quality of life questionnaire in both 
groups (case and control). The results were analyzed Hepatitis Monthly, Summer 2010; 10(3): 218-222
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by SPSS (Version 13) using chi-square, Fisher’s exact, 
Mann-Whitney  and  Wilcoxon  tests.  For  ethical 
issues,  after  the  study,  the  educational  pamphlets 
were also distributed to the control group and the 
correct method of injection of interferon was also 
taught to them. 
Results
The demographics data of the patients is shown 
and compared in Table 1. As is shown, no significant 
difference was observed between the two groups in 
this regard.
The Quality of Life Questionnaire for Chronic 
Liver  Disease  included  6  items:  fatigue,  activity, 
emotional symptoms, abdominal symptoms, systemic 
symptoms and worry, which were separately analyzed 
in the two groups before and after our intervention. 
Quality of life scores before and after intervention 
within groups has been shown in Table 2. Quality of 
life scores before and after intervention between the 
two groups has been shown in Table 3.
The  systemic  symptoms  of  the  control  group 
were significantly reduced after 12 weeks (P = 0.04) 
but other aspects including abdominal symptoms (P 
= 0.94), fatigue (P = 0.84), activity (P = 0.08), worry 
(P = 0.64) and emotional symptoms (P = 0.8) did 
not show a significant change after 12 weeks, in the 
control group.
In the case group there was a significant decrease 
in abdominal symptoms (P < 0.001), activity (P < 
0.001), worry (P < 0.001) and emotional symptoms 
(P < 0.001) after our intervention but no significant 
change  was  observed  in  systemic  symptoms  and 
fatigue in this group.
Using  the  Mann-Whitney  test,  we  found  a 
difference in three aspects between the cases and the 
controls after our intervention including abdominal 
symptoms  (P  =  0.01),  worry  (P  <  0.001)  and 
emotional symptoms(P < 0.001). The other aspects 
did not show any significant difference between the 
two groups.
The minimum quality of life score was 29 in this 
study and the maximum was 203. The mean quality 
of life scores in our controls was 154.5 before the 
study and 136.9 after 12 weeks but the Wilcoxon 
test did not show significant change between the two 
(P = 0.143).
In our cases, a quality of life score of 158.6 before 
intervention  had  increased  to  170  after  12  weeks, 
which was found to be significant using the Wilcoxon 
test (P < 0.001). Our data show that before treatment 
there had not been a significant difference between 
the two groups in quality of life scores (P = 0.351) but 
after intervention this difference becomes significant 
(P < 0.001).
Discussion
In this study the mean quality of life score in our 
controls was decreased after 3 months from 154 to 
137 which had been shown in other studies. In 2005, 
a study of different antiviral treatments on patients 
with hepatitis C by Kang and his colleagues showed 




Case Group P-value               
Statistical 
Test
Age 37.2 ± 9.5 40.3 ± 14.9 0.33 t- test
Sex (Percent) 0.381 chi-square
Male 24 (80%) 22 (73.3%)
Female 6 (20%) 8 (26.7%)
Level of Education fisher’s exact
Illiterate 0 3 (10%) 0.19
Primary  and 
Guidance School
15 (50%) 16 (53.3%)
Diploma  and 
Higher
15 (15%) 11 (36.7%)
Marital Status chi-square
Single 15 (50%) 13 (43.3%) 0.398
Married 15 (50%) 17 (56.6%)
Number of Children chi-square
3 or less 28 (93.3%) 23 (76.7%) 0.145
More than 3 2 (6.7%) 7 (23.3%)
Occupation fisher’s exact
Worker 7 (23.3%) 4 (13.3%) 0.076
Employee 4 (13.3%) 6 (20%)
Housekeeper 4 (13.3%) 4 (13.3%)
Student 0 6 (20%)
Retired 15 (50%) 10 (33.3%)
Duration of Disease chi-square
1-3 yr 22 (73.3%) 21 (70%) 1
3-6 yr 4 (13.3%) 5 (16.7%)
More than 6 yr 4 (13.3%) 4 (13.3%)
Hospitalization fisher’s exact
None 28 (93.3%) 30 (100%) 0.492
Once 2 (6.72%) 0
Hepatitis Type chi-square
Hepatitis C 20 (66.7%) 24 (80%) 0.243
Hepatitis B 10 (33.3%) 6 (20%)Hepatitis Monthly, Summer 2010; 10(3): 218-222
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that all treatment regimens had reduced the quality 
of life of patients in the primary stages of treatment 
and  side  effects  had  reduced  their  compliance 
and  adherence  to  treatment;  whereas  providing 
information to the patients about their treatment 
and  its  side  effects  will  increase  their  tolerance, 
compliance and adherence to antiviral therapy (17). 
In our cases, the mean quality of life score increased 
to 170 from its original 158 after three months. This 
increase is in accordance with previous studies on 
patients with liver disease in Tehran and Shiraz (16, 
18).
Certain  aspects  in  our  control  group  did  not 
show an increase after 12 months while the systemic 
symptoms  showed  a  decrease  during  follow  up. 
Previous studies show that the quality of life of the 
patient under antiviral treatment decreases in 12-24 
weeks after initiation of therapy and will eventually 
return to its baseline measurement after 24 weeks 
(12).  Fatigue  is  a  frequent  side  effect  of  hepatitis 
treatment  and  may  result  in  early  termination  of 
antiviral therapy (12).
In our cases, there was an increase in the scores 
of  abdominal  symptoms,  worry  and  emotional 
symptoms after 12 weeks. In our study, the quality 
of life score in our cases showed a significant increase 
after 12 weeks compared to the controls.
It seems that using simple measures against side 
effects like adequate hydration, light-to- moderate 
physical activity, scheduling the treatments for times 
when patients have less work or on weekends, using 
sedatives,  antipyretics  and  similar  measures  will 
greatly help the control of side effects which will 
consequently increase the satisfaction and quality of 
life of patients and ultimately result in tolerance of 
the treatment (19).
One of the drawbacks of this study is the limited 
number  of  the  population  studied,  which  should 
be  kept  in  mind  in  drawing  a  final  conclusion. 
Another  point  to  be  considered  is  the  different 
treatment regimens in hepatitis B and C (Interferon 
alpha and Ribavirin in hepatitis C and Interferon 
alpha in hepatitis B) which was a factor not taken 
into account in this study. The effect of different 
treatment regimens on hepatitis B and C could be 
the subject of a separate study. Emotional symptoms 
were different before intervention in the case and 
control  groups,  but  a  significant  increase  in  the 
quality of life score could justify a faster and greater 
increase in the emotional aspect.





Before After Before After
Scores Min-Max Mean SD Mean SD P Mean SD Mean SD P
Abdominal Symptoms 3-21 15.9 5.3 15.9 5.6 0.48 17.7 3.1 19.5 3.2 0.00
Activity 3-21 19.8 1.9 18.7 2.7 0.01 20 1.9 18 3.6 <0.001
Fatigue 5-35 23.4 8 23 7.2 0.68 26.3 6.3 26 6.9 0.08
Systemic Symptoms 5-35 28.5 5.2 26.4 6.6 0.03 29.9 4.1 29.1 5.1 0.29
Emotional 8-56 33.3 9.9 33 9.2 0.03 40.1 9.2 46.5 10.6 <0.001
Worry   5-35 22.3 6.8 21.9 7.4 0.21 24.1 5.3 30.2 6.3 <0.001
Total Score 29-203 154.5 28.5 136.9 30.6 158.6 21.4 170 23.6




Whitney Test Control Case Control Case
Scores Min-Max Mean SD Mean SD P Mean SD Mean SD P
Abdominal Symptoms 3-21 15.9 5.3 17.7 3.1 0.43 15.9 5.6 19.5 3.2 0.94
Activity 3-21 19.8 1.9 20 1.9 0.8 18.7 2.7 18 3.6 0.08
Fatigue 5-35 23.4 8 26.3 6.3 0.26 23 7.2 26 6.9 0.84
Systemic Symptoms 5-35 28.5 5.2 29.9 4.1 0.35 26.4 6.6 29.1 5.1 0.04
Emotional 8-56 33.3 9.9 40.1 9.2 0.006 33 9.2 46.5 10.6 0.8
Worry   5-35 22.3 6.8 24.1 5.3 0.06 21.9 7.4 30.2 6.3 0.64
Total Score 29-203 154.5 28.5 158.6 21.4 136.9 30.6 170 23.6Hepatitis Monthly, Summer 2010; 10(3): 218-222
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Conclusions
This  study  showed  that  continuous  education 
and follow up in chronic hepatitis B and C patients 
under  Interferon  alpha  treatment  could  greatly 
increase their adherence to interferon treatment and 
decrease  the  side  effects,  ultimately  resulting  in  a 
better quality of life.
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